Amicus Therapeutics announced the company will present initial preclinical data from its investigational adeno-associated viral gene therapy program for Pompe disease in a poster at the American Society of Gene & Cell Therapy, or ASGCT, 22nd Annual Meeting on April 30. “These represent the first set of preclinical results for the Pompe gene therapy which Amicus is currently developing in collaboration with the Gene Therapy Program of the Perelman School of Medicine at the University of Pennsylvania,” the company noted.
https://thefly.com/landingPageNews.php?id=2892685
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.